Inebilizumab Cdon

In this video, John H. Stone, MD, MPH, professor of medicine at Harvard Medical School, the Edward A. Fox Chair in Medicine at Massachusetts General Hospital, discusses an important facet of IgG4-related disease other rheumatologists and providers should be aware of.

The monoclonal antibody Uplizna met key endpoints in a phase 3 trial for the treatment of IgG4-related disease, marking the first time a placebo-controlled study has shown benefit in the condition, according to a press release from Amgen.

In patients with neuromyelitis optica spectrum disorder, transition from rituximab to inebilizumab was linked to suppression of attacks over a mean 19 months of treatment, according to research published in Frontiers in Neurology.

Uplizna appeared to benefit patients with neuromyelitis optica spectrum disorder who were previously treated with rituximab, according to study results published in Multiple Sclerosis and Related Disorders.

In this video, John H. Stone, MD, MPH, professor of medicine at Harvard Medical School, the Edward A. Fox Chair in Medicine at Massachusetts General Hospital, spotlights priority areas of research in the IgG4-related disease space.